Quick Answer
Tango Therapeutics, Inc. reported Operating Income of -$111.29 million for fiscal year 2025.
Tango Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$111.29M | +23.6% |
| 2024 | -$145.59M | -27.5% |
| 2023 | -$114.17M | -2.8% |
| 2022 | -$111.07M | -90.9% |
| 2021 | -$58.19M | -11.5% |
| 2020 | -$52.20M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.07M | +142.8% | +134.3% |
| June 30, 2025 | -$40.97M | -38.6% | +3.7% |
| March 31, 2025 | -$42.53M | -0.7% | -29.4% |
| September 30, 2024 | -$32.88M | -28.3% | -11.3% |
| June 30, 2024 | -$29.55M | -27.1% | +30.1% |
| March 31, 2024 | -$42.26M | -39.5% | -64.9% |
| September 30, 2023 | -$25.63M | +14.4% | -10.2% |
| June 30, 2023 | -$23.25M | +7.8% | +23.2% |
- Tango Therapeutics, Inc. showed an increase of +23.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Tango Therapeutics, Inc.’s operating income has declined by 113.2% (from -$52.20 million to -$111.29 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: